Literature DB >> 30012774

In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Robert A Smith1, Vincent H Wu2, Christopher G Zavala2, Dana N Raugi2, Selly Ba3, Moussa Seydi3, Geoffrey S Gottlieb2,4.   

Abstract

We examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. HIV-2 was sensitive to cabotegravir in single-cycle and spreading-infection assays, with 50% effective concentrations (EC50s) in the low to subnanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HIV-2; PrEP; West Africa; antiretroviral therapy; cabotegravir; human immunodeficiency virus; treatment

Mesh：

Substances：

Year:  2018        PMID： 30012774      PMCID： PMC6153831          DOI： 10.1128/AAC.01299-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  69 in total

1.  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Authors:  Tomokazu Yoshinaga; Masanori Kobayashi; Takahiro Seki; Shigeru Miki; Chiaki Wakasa-Morimoto; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.

Authors:  Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

3.  The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Sally S Leong; Kate M Parker; Mariah K Oakes; Papa Salif Sow; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

Authors:  Darius Armstrong-James; Justin Stebbing; Andrew Scourfield; Erasmus Smit; Bridget Ferns; Deenan Pillay; Mark Nelson
Journal:  Antiviral Res       Date:  2010-03-06       Impact factor: 5.970

5.  Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

Authors:  Berta Rodés; Julie Sheldon; Carlos Toro; Victoria Jiménez; Miguel Angel Alvarez; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

6.  Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

Authors:  Evan T Brower; Usman M Bacha; Yuko Kawasaki; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2008-02-28       Impact factor: 2.817

7.  Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

Authors:  Myriam Witvrouw; Christophe Pannecouque; William M Switzer; Thomas M Folks; Erik De Clercq; Walid Heneine
Journal:  Antivir Ther       Date:  2004-02

8.  HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.

Authors:  Joana Cavaco-Silva; Ana Abecasis; Ana Cláudia Miranda; José Poças; Jorge Narciso; Maria João Águas; Fernando Maltez; Isabel Almeida; Isabel Germano; António Diniz; Maria de Fátima Gonçalves; Perpétua Gomes; Celso Cunha; Ricardo Jorge Camacho
Journal:  PLoS One       Date:  2014-03-28       Impact factor: 3.240

9.  First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Authors:  Sophie Matheron; Diane Descamps; Sebastien Gallien; Amel Besseghir; Pierre Sellier; Laurent Blum; Emmanuel Mortier; Charlotte Charpentier; Roland Tubiana; Florence Damond; Gilles Peytavin; Diane Ponscarme; Fideline Collin; Francoise Brun-Vezinet; Genevieve Chene
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

Review 10.  HIV-2: the forgotten AIDS virus.

Authors:  Thushan I de Silva; Matthew Cotten; Sarah L Rowland-Jones
Journal:  Trends Microbiol       Date:  2008-10-27       Impact factor: 17.079
View more
  4 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.

Authors:  Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

3.  Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability.

Authors:  Shujing Xu; Lin Sun; Alexej Dick; Waleed A Zalloum; Tianguang Huang; Megan E Meuser; Xujie Zhang; Yucen Tao; Srinivasulu Cherukupalli; Dang Ding; Xiao Ding; Shenghua Gao; Xiangyi Jiang; Dongwei Kang; Erik De Clercq; Christophe Pannecouque; Simon Cocklin; Xinyong Liu; Peng Zhan
Journal:  Eur J Med Chem       Date:  2021-10-09       Impact factor: 7.088

4.  A year-long extended release nanoformulated cabotegravir prodrug.

Authors:  Tanmay A Kulkarni; Aditya N Bade; Brady Sillman; Bhagya Laxmi Dyavar Shetty; Melinda S Wojtkiewicz; Nagsen Gautam; James R Hilaire; Sruthi Sravanam; Adam Szlachetka; Benjamin G Lamberty; Brenda M Morsey; Howard S Fox; Yazen Alnouti; JoEllyn M McMillan; R Lee Mosley; Jane Meza; Paul L Domanico; Tai-Yuen Yue; Gary Moore; Benson J Edagwa; Howard E Gendelman
Journal:  Nat Mater       Date:  2020-04-27       Impact factor: 47.656
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.